5,8-二氮杂螺[3.5]壬烷-5-羧酸叔丁酯 | 886766-34-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 5,8-二氮杂螺[3.5]壬烷-5-羧酸叔丁酯
• 英文名称: tert-butyl 5,8-diazaspiro[3.5]nonane-5-carboxylate
• CAS: 886766-34-3
• 化学式: C₁₂H₂₂N₂O₂
• 分子量: 226.319
• InChiKey: YZZOBJMUDHAXFE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  5,8-二氮杂螺[3.5]壬烷-5-羧酸叔丁酯 在 盐酸 、 potassium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 N-甲基吡咯烷酮 、 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.5h， 生成 4-chloro-6-fluoro-3-(8-(5-fluoropyrimidin-2-yl)-5,8-diazaspiro[3.5]nonan-5-yl)-1-tosyl-1H-indazole
  参考文献：
  名称：

  [EN] SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF
  [FR] DÉRIVÉS CYCLIQUES DE SULFONYLE, COMPOSITIONS ET PROCÉDÉS ASSOCIÉS

  摘要：

  The invention provides novel sulfonyl cyclic derivatives, and compositions and methods of preparation and use thereof, that are useful in treating various diseases and disorders related to TRPML activities such as lysosome storage diseases, muscular dystrophy, neurodegenerative diseases, oxidative stress or reactive oxygen species (ROS) related diseases, metabolic diseases, metastatic cancer, and ageing.

  公开号：

  WO2023235305A2

文献信息

• [EN] PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN<br/>[FR] DÉRIVÉS DE PYRAZOLYLE EN TANT QU'INHIBITEURS DE LA PROTÉINE MUTANTE KRAS
  申请人：NOVARTIS AG

  公开号：WO2022269508A1

  公开（公告）日：2022-12-29

  The present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, and the therapeutic uses of said compound. The present invention further provides a pharmaceutical composition comprising said compound.

  本发明提供了式(I)的化合物或其药学上可接受的盐，以及该化合物的治疗用途。本发明还提供了包含该化合物的药物组合物。
• Mutant IDH1 inhibitors useful for treating cancer
  申请人：THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICE

  公开号：US10703746B2

  公开（公告）日：2020-07-07

  Compounds of Formula I and Formula II and the pharmaceutically acceptable salts thereof are disclosed The variables A, B, Y, Z, X1, X2, R1-4 and R13-18 are disclosed herein. The compounds are useful for treating cancer disorders, especially those involving mutant IDH1 enzymes. Pharmaceutical compositions containing compounds of Formula I or Formula II and methods of treatment comprising administering compounds of Formula I and Formula II are also disclosed.

  公开了式 I 和式 II 的化合物及其药学上可接受的盐 本文公开了变量 A、B、Y、Z、X1、X2、R1-4 和 R13-18。这些化合物可用于治疗癌症疾病，特别是涉及突变 IDH1 酶的疾病。还公开了含有式 I 或式 II 化合物的药物组合物以及包括施用式 I 和式 II 化合物的治疗方法。
• ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20210380574A1

  公开（公告）日：2021-12-09

  The present invention encompasses compounds of formula (I) wherein R 1a , R 1b , R 2a , R 2b , Z, R 3 to R 5 , A, p, U, V, W, L and E have the meanings given in the claims and specification, their use as inhibitors of mutant Ras family proteins, pharmaceutical compositions and preparations containing such compounds and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
• BICYCLIC PYRAZOLE BRUTON'S TYROSINE KINASE INHIBITORS
  申请人：AbbVie Inc.

  公开号：US20220213092A1

  公开（公告）日：2022-07-07

  The present invention provides for compounds of formula (I) wherein A, R 1 , R 2 , R 4 , W, m, and n have any of the values defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL and/or SLL.
• [EN] BICYCLIC PYRAZOLE BRUTON'S TYROSINE KINASE INHIBITORS<br/>[FR] INHIBITEURS BICYCLIQUES DE LA TYROSINE KINASE DE BRUTON
  申请人：[en]ABBVIE INC.

  公开号：WO2022132997A1

  公开（公告）日：2022-06-23

  The present invention provides for compounds of formula (I); wherein A, R1, R2, R4, W, m, and n have any of the values defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL and/or SLL.